Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue and Mallinckrodt resolve OxyContin patent suit

This article was originally published in Scrip

Executive Summary

Purdue Pharma and Mallinckrodthave signed an agreement to end their OxyContin (oxycodone controlled-release) tablets patent infringement suit which has been pending in a district court in New York. Mallinckrodt acknowledges the validity and enforceability of Purdue's patents. At the same time, Purdue has agreed to grant Mallinckrodt a royalty-bearing licence to sell limited quantities of versions of 10mg, 20mg, 40mg and 80mg extended-release oxycodone tablets. The District Court for the Southern District of New York has repeatedly ruled in favour of Purdue on the enforceability of its US patents covering OxyContin.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC032190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel